Search Team

Search by Last Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Banner image

IP LitigationLife Sciences

Biogen Dodges IPR Bullet on Key Tysabri® Patents

October 20, 2016

IP LitigationLife Sciences

Biogen Dodges IPR Bullet on Key Tysabri® Patents

October 20, 2016

Back to Fish's Litigation Blog

 

On Monday, the PTAB issued its ruling denying institution of three IPRs challenging Biogen’s patents claiming formulations and methods of treatment using natalizumab. Specifically, the PTAB denied institution of IPR2016-00912, IPR2016-00915, and IPR2016-00916, all brought by India’s Swiss Pharma International, targeting Biogen’s U.S. Patent Nos. 8,815,236, 8,349,321, and 8,900,577, which issued between 2013-2014. In reaching these decisions, the PTAB concluded that Swiss Pharma had not established a reasonable likelihood that the 32 challenged claims are rendered obvious by the prior art.

Natalizumab is a humanized monoclonal antibody used in the treatment of multiple sclerosis (MS) and Crohn’s disease. Currently marketed as Tysabri®, it brings in roughly $2 billion annually in sales for the Massachusetts-based Biogen, Inc. The three patents at issue cover formulations of a range of high-dose, stable natalizumab concentrations (20-150 mg/mL), as well as methods of treating MS patients with these formulations. Swiss Pharma challenged claims covering either the 20 mg/mL dosage or the full 20-150 mg/mL dosage range, but chose not to challenge the individual claims reciting only the 150 mg/mL dosage.

In its petitions, Swiss Pharma argued that the three patents are rendered obvious under 35 U.S.C. § 103(a) in light of a series of prior art references which primarily describe unrelated antibodies or small molecules. Only one reference discloses natalizumab, but lacks both the claimed excipients and the claimed dosage range. The rest of the references describing unrelated antibodies teach the claimed excipients, but do not teach a high dosage. Rather, the highest antibody concentration disclosed is 10 mg/mL, only half of the lowest claimed natalizumab dosage. While Swiss Pharma asserted that, once natalizumab was published, increasing the dosage to 20 mg/mL was “nothing more than routine optimization,” the PTAB disagreed. The PTAB found that Swiss Pharma “has failed to provide sufficient and credible evidence that the combination renders obvious a natalizumab formulation containing about 20 mg/mL to about 150 mg/mL of natalizumab.”

Although these decisions are unappealable, other challenges could be raised against these patents in potential future litigation. Additionally, Biogen and others hold over 90 patents that also recite natalizumab in their claims. These patents cover a range of formulations and methods of treatment for a variety of diseases, including MS. However, to date, the three patents at issue here are the only ones which have been challenged at the Patent Office. Unless they are challenged further, they will remain valid through 2024.

Related Tags

PTAB
Biogen

Blog Authors

Headshot
Casey Kraning-Rush | Law Clerk

Casey Kraning-Rush, Ph.D., is a litigation law clerk in Fish & Richardson’s Delaware office. Dr. Kraning-Rush was previously a summer associate with the firm in 2014 and 2015, where she focused primarily on patent litigation. She earned her Ph.D. in Biomedical Engineering and has...

Headshot
Jenny Shmuel, Ph.D. | Associate

Jenny Shmuel is an Associate in the Boston office of Fish & Richardson. She was a Summer Associate with the firm in 2011. Ms. Shmuel has worked on a range of intellectual property matters, including patent litigation in the software and medical device fields, copyright...

Headshot
Tasha M. Francis, Ph.D. | Associate

Tasha Francis, Ph.D. is an associate in Fish & Richardson’s Twin Cities office, practices intellectual property litigation with an emphasis on patent litigation. Dr. Francis has represented plaintiffs and defendants in cases involving medical devices, biotechnology...

Leave a Reply

Your email address will not be published. Required fields are marked *